Comparing 3-BP with complementary therapies to the cost, effectiveness of conventional immunotherapy drugs
Many healthcare systems rely on a mechanistic view of health and how to cure disease. This view developed in the late 19th century with the discoveries of Louis Pasteur. He experimented with pasteurization to prevent spoilage in beer and milk.
Pasteur is one of the fathers of germ theory and involved in the development of the first vaccines. The germ theory has success in treating or preventing pneumonia, syphilis, malaria, polio, etc.
In spite of its success, the conventional model of medicine has its limitations. Its strengths have evolved into some major weaknesses. Both medical care professionals and patients have become used to the idea that we can take a drug to get a quick.
But this does not identify the root causes of disease. For example, why change my diet, eliminate sugar, and get more exercise to control my Type 2 diabetes? I can take a pill or inject insulin!
Yet, more dysfunctional is the current range of treatment options for cancer. The Emperor of All Maladies by Dr. Siddhartha Mukherjee details the evolution of cancer treatment. The book also addresses research on treatments including genetic and immunotherapy therapy.
“The same old ideas, and it's all crap”
But it is interesting to note what Dr. James Watson, who worked on the double helix (DNA) discovery, said about cancer genetic research:
“The depressing thing about the ‘cancer moonshot' is that it's the same old people getting together, forming committees, and the same old ideas, and it's all crap …” 
Genetic research will not develop meaningful treatments other than a few specific areas. This is because the paradigm of cancer being a genetic cause has not changed. But there is an up and coming idea that cancer is a metabolic disease.
Did You Know
Immunotherapy is hot
Immunotherapy is one of the hottest areas of research. It is somewhat more effective, has fewer side effects, but is expensive. This makes it attractive to the drugs companies. Drug companies are not motivated to develop drugs or treatment protocols that are not patentable, like the 3BP that Daysprings uses.
The traditional treatments for most cancers continue to be surgery, chemotherapy, and radiation. There are other treatments for certain types of cancer — hormone therapy, bone marrow replacement, etc.
All treatments have some side effects, but the most common treatment is chemotherapy. It has severe side effects because chemo damages healthy cells and the immune system — both key to long-term health.
Analysis of the data claims the effectiveness of chemo for Stage IV cancers is around 2 percent. (It is higher for certain types of cancer, like childhood leukemia or testicular cancer.) Chemo side effects also may cause permanent damage or death. Additionally, it is expensive.
Limitations of cancer treatments are obvious. Now, cancer researchers have branched out into other possible treatments.
Still, drug companies, hospitals, and doctors make a lot of money with chemotherapy.
Immunotherapy is one of the hottest areas of research. It is somewhat more effective, has fewer side effects, but is expensive. This makes it attractive to the drugs companies. Several immunotherapy drugs were released in the past few years.
Drug companies are not motivated to develop drugs or treatment protocols that are not patentable, like the 3-BP that Daysprings uses. They want to continue to sell expensive drugs that maintain profit margins.
But desperate cancer patients will go bankrupt to save or extend their life. Yet, even with insurance, the cost of these immunotherapy drugs is unimaginable.
In his presentation at the 2015 American Society of Clinical Oncologists], Dr. Leonard Saltz showed the cost of immunotherapy drugs: [2, 3]
A cost 4,000 times more than gold!
Opdivo costs $29 per mg, whereas Yervoy costs $157 per mg. Yervoy costs 4,000 times more than gold!
In the latest trial, the cost of using Yervoy alone was $158,282 to get an extra 2.4 months. The cost of Opdivo alone was $103,220 for an extra 6.9 months.
Combined, that costs $295,566 for an extra 11.4 months.
Did You Know
High Cost of Living
In the latest trial, the cost of using Yervoy alone was $158,282 to get an extra 2.4 months. The cost of Opdivo alone was $103,220 for an extra 6.9 months. Combined, that costs $295,566 for an extra 11.4 months. For patients on Medicare, and those whose insurance requires a 20 percent co-pay, it will cost $60,000 out of pocket for one year of the treatment.
For patients on Medicare, and those whose insurance requires a 20 percent co-pay, it will cost $60,000 out of pocket for one year of the treatment.
Pembrolizumab is an immunotherapy drug approved for melanoma. The brand name is Keytruda and it currently costs around $14,500 per month. It is being studied on 20 different types of cancer. It has shown anti-tumor activity in 13 tumor types like small cell lung cancer, esophageal cancer, and ovarian cancer.
But the latest clinical trials are using a dose five times higher than approved for melanoma. It also costs about $83,000 per month. Yes, per month. For a 165-pound patient, Keytruda at the higher dose will cost more than $1 million per patient per year. (26 doses per year at $51.79 per mg.)
The FDA-approved Opdivo to treat squamous non-small cell lung cancer. At ASCO 2015, researchers presented a study using Opdivo on non-squamous non-small-cell lung cancer. The late-stage study showed that patients receiving Opdivo had a median survival of 12.2 months. Compare that to 9.4 months for patients taking the chemo drug Docetaxel. Adverse effects also were less severe.
Again, we're talking about the median; half the patients lived more than 12 months, half of them did not. Comparing the two median patients, one got an extra 3 months of life from a $100,000 therapy.
For the 589,430 people dying each year from metastatic cancer, this will cost $174 billion dollars. That is per year for the drug treatment with no other costs included.
So, what is the take-home message? Patented immunotherapy drugs are outrageously expensive and not tremendously effective. And yet, profit-oriented pharmaceutical companies still push these drugs to doctors. And the companies tout their drugs on TV.
Our holistic approach is more beneficial
At Dayspring, our holistic approach is more beneficial to find the root cause of cancer. A metabolic treatment, 3-bromopyruvate, is the backbone of our protocol. Dr. Peter Pederson has researched 3-BP for almost 20 years at Johns Hopkins University. (JHU is one of the most prestigious cancer institutes in the world.)
3-BP is an off-the-shelf chemical and not patentable or profitable to drug companies. When administered properly, it is more effective than conventional chemotherapy.  3-BP also has limited side effects. It attacks only cancer cells; untouched are normal cells and the immune system.
Dayspring adds complementary therapies to the 3-BP protocol. This helpsto detoxify the body and enhance immune function. Together, this treatment helps the body re-establish long-term health. This is not a short-term extension of life.
The root causes of cancer are different for everybody. At Dayspring, we customize treatment for each patient. Call Dayspring at (800) 351-5913 for a cost-effective and productive cancer treatment plan.
Clinics that offer
3-Bromopyruvate (3-BP) Metabolic Therapy
Cancer Tutor Verified
Dr. Andrew Dickens is a naturopathic physician at Dayspring Cancer Center in Scottsdale, Arizona. He is a member of the Arizona Naturopathic Medical Association. The Dayspring treatment strategy for cancer incorporates the best mainstream and alternative modalities, customized for your individual needs.
- DNA pioneer James Watson: The cancer moonshot is ‘crap’ | STAT | https://www.statnews.com/2016/07/20/james-watson-cancer/
- Andrews A. Treating with Checkpoint Inhibitors—Figure $1 Million per Patient. American Health & Drug Benefits. 2015;8(Spec Issue):9.
- Chris Beat Cancer | “Immunotherapy Drugs: New Hope or More Hype?” | https://www.chrisbeatcancer.com/immunotherapy-drugs-new-hope-or-more-hype/
- Ko, Y. H., Verhoeven, H. A., Lee, M. J., Corbin, D. J., Vogl, T. J., Pedersen, P. L. | 2012 | A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside | JO – Journal of Bioenergetics and Biomembranes | https://doi.org/10.1007/s10863-012-9417-4